BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
基本信息
- 批准号:10451498
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:Advanced Glycosylation End ProductsAffectAfghanistanAgeAge-YearsAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAmyloidAmyloid beta-ProteinAmyloidosisAnimalsAntibodiesAntigensAntisense OligonucleotidesApolipoprotein EApoptoticAreaAttentionAutopsyAwardBeerBindingBloodBlood VesselsBostonBrainBrain ConcussionBudgetsC9ORF72CASP1 geneCardiovascular DiseasesCardiovascular PhysiologyCathepsins BCell DeathCerebral IschemiaChronic DiseaseChronic Kidney FailureClinicClinicalClinical SciencesCollaborationsCommon Acute Lymphoblastic LeukemiaComplementComplications of Diabetes MellitusDiabetes MellitusDiseaseDisease modelDoctor of PhilosophyFGFR4 geneFamilyFloridaFunctional disorderGene ActivationGeneral PopulationGenerationsGenesGoalsGrantHealthHealthcareHigh Fat DietHuntington DiseaseHydrophobicityHyperlipidemiaImpaired cognitionInflammasomeInflammationInflammatoryInjuryInterleukin-1IraqJournalsLeft Ventricular HypertrophyLengthLentivirus VectorLigandsLiverLow Density Lipoprotein ReceptorMaintenanceMediatingMedical centerMemory LossMetabolic DiseasesMetabolic syndromeMetalloproteasesModelingMusNatural ImmunityNatureNeprilysinNeurodegenerative DisordersNeurologicNeurological outcomeObesityOutcomeOxidesPaperParkinson DiseasePathogenesisPathologic ProcessesPathway interactionsPeer ReviewPeptidesPharmacologic SubstancePharmacy facilityPhospholipidsPlayPopulationPost-Traumatic Stress DisordersProcessProductionProtein IsoformsProteinsPublishingRattusReactive Oxygen SpeciesReagentRecoveryResearchRiskRisk FactorsRodent ModelRoleScienceScientistSenile PlaquesSerum Amyloid P-ComponentSerum amyloid A proteinSideSignal PathwaySignal TransductionSodium ChlorideSpinal cord injuryStrokeTauopathiesTestingTherapeuticTherapeutic InterventionTissuesTransgenic AnimalsTransgenic OrganismsTranslatingTraumaTraumatic Brain InjuryUniversitiesVeteransVirus InhibitorsVitamin DWorkZincagedamyloid formationamyloidogenesiscareerchronic traumatic encephalopathycognitive functioncollegecytokinedesigndirect applicationhealth disparityhuman diseaseimmunoglobulin receptorimprovedin vivoindexinginhibitorinterestislet amyloid polypeptideknockout genelearning abilitymilitary veteranmouse modelnervous system disorderneuroinflammationneuromuscularneuron lossnew therapeutic targetnoveloverexpressionprofessorprogramsprotein TDP-43receptorreceptor for advanced glycation endproductsrelating to nervous systemsmall molecule inhibitorsoluble RAGEstroke modelstroke outcomesuperoxide dismutase 1synucleintau Proteinstherapeutic developmenttumor
项目摘要
The PI, Mark S. Kindy, Ph.D., has been studying the mechanisms and pathways associated with a number of
neurological and neurodegenerative disorders. These include, Alzheimer’s disease (AD), stroke, Parkinson’s
disease (PD), traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), spinal cord injury (SCI),
among others. All of these disorders are afflictions that are present in the VA population and contribute
significantly to the overall health of the Veterans. The overarching goal is to understand the mechanisms
involved in the disease processes and to develop therapeutic approaches to treat them. I have three basic areas
of research that we focus on. The first program is centered around stroke and the impact of negative vascular
health factors (such as: obesity, diabetes, age, salt sensitivity hyperlipidemia, and hypertensivity) on the
induction of reactive oxygen species (ROS) production and activation of the inflammation (inflammasome). We
have shown that aged animals with the risk factors have worse outcomes and recovery is exacerbated due to
the presence of both systemic and neuroinflammation. The generation of better clinical models of stroke to test
these risk factors and health disparities following injury. Studies using low-density lipoprotein receptor (ldlr)
deficient mice with and without high fat diet are being used to study the impact of oxidized phospholipids (OxPLs)
on stroke outcomes. Mice expressing OxPL antibodies will be tested for protection from stroke. Finally, we are
examining the impact of chronic kidney disease, left ventricular hypertrophy and FGF23 on stroke and stroke
outcomes. Mice with targeted deletion of the fgfr4 gene or overexpression of the FGF23 are being examined for
stroke outcomes. These studies will better capture the true nature of veterans and civilians who have a stroke
and provide a better approach to treating the disease. A second line of research focuses on the role of serum
amyloid A (SAA) proteins in the pathogenesis of stroke. Recent studies have implicated SAAs in innate immunity
and various disorders, however the precise mechanism eludes us. SAAs are elevated following stroke (cerebral
ischemia) and TBI, and our studies show that SAA increases the cytokine interleukin-1 (IL-1), which is
mediated by Nod-like receptor protein 3 (NLRP3) inflammasome, cathepsin B and caspase-1 and may play a
role in the pathogenesis of neurological disorders. Using transgenic and gene deleted mice as well as AAV
expressing constructs we are evaluating the impact of SAA on stroke and other neurological diseases. Another
line of research focuses on serum amyloid P component (SAP), which is found in all amyloids and studies have
suggested that it plays an integral role in the formation, progression, and maintenance of the amyloid disease
processes. The amyloid diseases include: AD, PD (tau, -synuclein, TDP-43), tauopathies, CTE, ALS (SOD1,
TDP-43, C9ORF72), systemic amyloids (AA, TTR, amylin), Huntington’s disease (HD), ABri and ADan.
Inflammation modifies SAP function, and inflammatory signaling pathways impair cognitive function in vivo. Our
long-term goal is to determine the mechanisms regulating SAP function, particularly within the setting of AD and
inflammatory diseases. Consequently, the objective of this grant is to characterize the role for SAP in
inflammation and AD. We have developed and amassed various transgenic and gene deleted mice as well as
viruses and inhibitors to determine the impact of SAP in the amyloid diseases. Since both SAA and SAP are
produced mainly in the liver, we are working with Ionis Pharmaceuticals in the design and testing of antisense
oligonucleotides (ASOs) as therapeutic approaches to these disorders. In addition, we are working with
clinicians at the Haley VA and other VAs (Boston CTE Center) and Universities around the US to correlate the
animal studies with human disease. Using autopsy tissues, blood, CSF and other reagents to validate the studies
in our mouse and rat models. This is critical to our basic understanding of the disease process and in the
development of therapeutics for treatment.
PI Mark S. Kindy 博士一直在研究与许多相关的机制和途径
神经系统和神经退行性疾病。其中包括阿尔茨海默病 (AD)、中风、帕金森病
疾病(PD)、创伤性脑损伤(TBI)、慢性创伤性脑病(CTE)、脊髓损伤(SCI)、
除其他外。所有这些疾病都是退伍军人群体中存在的痛苦,并导致
对退伍军人的整体健康有显着影响。首要目标是了解机制
参与疾病过程并开发治疗方法。我有三个基本领域
我们关注的研究。第一个项目以中风和负面血管的影响为中心
健康因素(如:肥胖、糖尿病、年龄、盐敏感性、高脂血症、高血压)对
诱导活性氧 (ROS) 产生和炎症激活(炎症小体)。我们
已经表明,具有危险因素的老年动物的结果更差,并且由于以下原因而导致恢复加剧
全身炎症和神经炎症的存在。生成更好的中风临床模型进行测试
这些危险因素和受伤后的健康差异。使用低密度脂蛋白受体 (ldlr) 的研究
有或没有高脂肪饮食的缺陷小鼠被用来研究氧化磷脂 (OxPL) 的影响
关于中风结果。将测试表达 OxPL 抗体的小鼠是否能预防中风。最后,我们是
检查慢性肾病、左心室肥厚和 FGF23 对中风和中风的影响
结果。正在检查 fgfr4 基因定向缺失或 FGF23 过度表达的小鼠
中风结果。这些研究将更好地了解中风退伍军人和平民的真实本质
并提供更好的治疗该疾病的方法。第二条研究重点是血清的作用
淀粉样蛋白 A (SAA) 蛋白在中风发病机制中的作用。最近的研究表明 SAA 与先天免疫有关
和各种疾病,但确切的机制我们却不清楚。中风后 SAA 升高(脑卒中)
缺血)和 TBI,我们的研究表明 SAA 会增加细胞因子白细胞介素 1 (IL-1),这是
由 Nod 样受体蛋白 3 (NLRP3) 炎性体、组织蛋白酶 B 和 caspase-1 介导,可能发挥
在神经系统疾病的发病机制中的作用。使用转基因和基因删除小鼠以及 AAV
我们正在评估 SAA 对中风和其他神经系统疾病的影响。其他
研究方向集中于血清淀粉样蛋白 P 成分 (SAP),它存在于所有淀粉样蛋白中,并且有研究表明
表明它在淀粉样蛋白疾病的形成、进展和维持中起着不可或缺的作用
流程。淀粉样蛋白疾病包括:AD、PD(tau、α-突触核蛋白、TDP-43)、tau蛋白病、CTE、ALS(SOD1、
TDP-43、C9ORF72)、系统性淀粉样蛋白(AA、TTR、胰淀素)、亨廷顿病 (HD)、ABri 和 ADan。
炎症改变 SAP 功能,炎症信号通路损害体内认知功能。我们的
长期目标是确定调节 SAP 功能的机制,特别是在 AD 和
炎症性疾病。因此,这笔赠款的目的是描述 SAP 在以下方面的作用:
炎症和AD。我们开发并积累了各种转基因和基因缺失小鼠以及
病毒和抑制剂以确定 SAP 在淀粉样蛋白疾病中的影响。由于 SAA 和 SAP 都是
主要在肝脏中产生,我们正在与 Ionis Pharmaceuticals 合作设计和测试反义药物
寡核苷酸(ASO)作为这些疾病的治疗方法。此外,我们正在与
Haley VA 和其他 VA(波士顿 CTE 中心)以及美国各地大学的临床医生将
人类疾病的动物研究。使用尸检组织、血液、脑脊液和其他试剂来验证研究
在我们的小鼠和大鼠模型中。这对于我们对疾病过程和疾病的基本了解至关重要
开发治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK S. KINDY其他文献
MARK S. KINDY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK S. KINDY', 18)}}的其他基金
ShEEP Request for 4D Bioprinting-Biofabrication of stimuli-responsive materials
ShEEP 请求 4D 生物打印-刺激响应材料的生物制造
- 批准号:
9795834 - 财政年份:2019
- 资助金额:
-- - 项目类别:
ShEEP Request for CLARITY Optimized Light sheet Microscope for high speed imaging of large clarified samples at high resolution
ShEEP 请求 CLARITY 优化光片显微镜,以高分辨率对大型澄清样品进行高速成像
- 批准号:
9363118 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Targeted Delivery of Antioxidant Drugs Following Cerebral Ischemic Injury
脑缺血性损伤后抗氧化药物的靶向递送
- 批准号:
9040017 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Targeted Delivery of Antioxidant Drugs Following Cerebral Ischemic Injury
脑缺血性损伤后抗氧化药物的靶向递送
- 批准号:
9812773 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Targeted Delivery of Antioxidant Drugs Following Cerebral Ischemic Injury
脑缺血性损伤后抗氧化药物的靶向递送
- 批准号:
9398913 - 财政年份:2014
- 资助金额:
-- - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists